← Back to Search

Behavioral Intervention

Personalized Text Messaging for Type 2 Diabetes (REINFORCE2 Trial)

Q: Is age a factor for the inclusion criteria within this research project?

This experiment necessitates that the participants be between 18 and 84 years old. For those younger than 18 there are 64 trial opportunities, while 741 trials will accept individuals over 65.

Q: Is recruitment for this research endeavor still ongoing?

According to the clinicaltrials.gov listing, this medical trial is no longer recruiting patients; although initial postings began on April 1st 2023, the site was most recently updated on February 23rd of that same year. Despite its inactivity, there are 867 other studies actively enrolling participants currently.

Q: To whom is this clinical trial accessible?

This clinical trial is accepting 60 patients that have been diagnosed with <a href="https://www.withpower.com/clinical-trials/type-2-diabetes">type 2 diabetes</a> and are between 18-84 years old. To be eligible, they must fulfill the following conditions: possess a T2DM diagnosis, take 1 to 3 daily oral medications for their diabetes, record an HbA1c of 7.5% or higher recently, display below par adherence as noted by a PDC lower than 0.80; own a smartphone which only they utilize; and know either English or Spanish sufficiently well.

N/A

Waitlist Available

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of Type 2 Diabetes Mellitus (T2DM)

Prescribed between 1-3 daily oral medications for diabetes

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

REINFORCE2 Trial Summary

This trial will test if personalized text messages can help people with type 2 diabetes take their meds, with the goal of improving health outcomes.

Who is the study for?

This trial is for adults aged 18-84 with type 2 diabetes who have a recent HbA1c level of at least 7.5%, use a smartphone, understand English or Spanish, take 1-3 daily oral diabetes meds, and have been less than ideally consistent with their medication (PDC <0.80). It's not for those getting daily help with meds or unwilling to switch to electronic pill bottles.Check my eligibility

What is being tested?

The study tests if personalized text messages based on reinforcement learning can improve medication adherence in type 2 diabetes patients compared to standard texts. Participants will be randomly assigned to receive either tailored messages that adapt over time or generic ones, both potentially up to daily.See study design

What are the potential side effects?

Since the intervention involves only behavioral messaging via text and does not include medications or medical procedures, there are no direct physical side effects expected from participating in this trial.

REINFORCE2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with Type 2 Diabetes.

Select...

I take 1 to 3 pills daily for my diabetes.

REINFORCE2 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Diabetes medication adherence

Secondary outcome measures

Glycemic control

REINFORCE2 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Reinforcement Learning Intervention ArmExperimental Treatment1 Intervention

Up to daily, tailored text messages.

Group II: Control ArmActive Control1 Intervention

Up to daily, untailored text messages.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Reinforcement Learning

2021

N/A

~60

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH

1,669 Previous Clinical Trials

28,005,054 Total Patients Enrolled

Brigham and Women's HospitalLead Sponsor

1,609 Previous Clinical Trials

11,470,267 Total Patients Enrolled

Boston Medical CenterOTHER

382 Previous Clinical Trials

869,339 Total Patients Enrolled

Media Library

Reinforcement Learning (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05742685 — N/A

Type 2 Diabetes Research Study Groups: Reinforcement Learning Intervention Arm, Control Arm

Type 2 Diabetes Clinical Trial 2023: Reinforcement Learning Highlights & Side Effects. Trial Name: NCT05742685 — N/A

Reinforcement Learning (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05742685 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is age a factor for the inclusion criteria within this research project?

"This experiment necessitates that the participants be between 18 and 84 years old. For those younger than 18 there are 64 trial opportunities, while 741 trials will accept individuals over 65."

Answered by AI

Is recruitment for this research endeavor still ongoing?

"According to the clinicaltrials.gov listing, this medical trial is no longer recruiting patients; although initial postings began on April 1st 2023, the site was most recently updated on February 23rd of that same year. Despite its inactivity, there are 867 other studies actively enrolling participants currently."

Answered by AI

To whom is this clinical trial accessible?

"This clinical trial is accepting 60 patients that have been diagnosed with type 2 diabetes and are between 18-84 years old. To be eligible, they must fulfill the following conditions: possess a T2DM diagnosis, take 1 to 3 daily oral medications for their diabetes, record an HbA1c of 7.5% or higher recently, display below par adherence as noted by a PDC lower than 0.80; own a smartphone which only they utilize; and know either English or Spanish sufficiently well."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Refinement and Adaption of Reinforcement Learning to Personalize Behavioral Messaging for Healthy Habits

Julie Lauffenburger 2023. "Refinement and Adaption of Reinforcement Learning to Personalize Behavioral Messaging for Healthy Habits". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05742685.